Cover article published! The latest findings of Xinda Bio's new TIM-3 monoantitonic resistance have been published

Immunotherapy, represented by PD-1 monoantigen and CTLA-4 monoantigen, has changed the lives of many patients with advanced cancer.
, however, only a small number of patients with advanced cancer responded to the single-drug treatment of these immuno-checkpoint inhibitors.
in certain tumor types, such as colorectal and stomach cancers, a large number of patients are difficult to treat with CTLA-4 monoantial and PD-1 monoantial.
Therefore, there is a clinically urgent need for other co-inhibitory bodies that can work together with PD-1 or CTLA-4 to inhibit T-cell responses, or other co-inhibitors that play a major negative role in the regulation of certain tumor types of immune response, tim-3 is one of them.
TIM-3 is a negatively regulated immune checkpoint present in different types of immune cells.
TIM-3 signaling path, plays an important role in the regulation of T cell activity and quantity, and can participate in the immunosuppression and progression of tumors by mediating apoptosis.
study found that TIM-3 antibodies not only have the potential to inhibit tumor growth, but are also expected to work in synergy with PD-1/PD-L1 antibodies to treat patients who are resistant to PD-1/PD-L1.
, TIM-3 has become a hot target in the field of cancer immunotherapy.
, HOWever, TIM-3 has a variety of matings, and these different mating binding points make it difficult to completely block TIM-3 signal conduction using a single antibody.
photo source: Resources: In this article published in Antibody Therapeutics, researchers describe a unique humanized anti-TIM-3 monoclonal antibody, IBI104.
IBI104 is expected to overcome the challenge of "using a single antibody to completely block TIM-3 signaling," according to a Xinda Bio news release.
, IBI104 is unique in that it is a strong internal swallowing of TIM-3 blocking antibody, so as to achieve the goal of completely blocking signals from different TIM-3 media, and may have better blocking effect and efficacy.
specifically, in the ELISA (Enzyme-Linked Immunosorption Experiment) analysis, IBI104 can block the interaction between phosphatidylserine and TIM-3 without interfering with the inflammation and apoptosis of TIM-3 and semi-lactoclin 9 (a carbohydrate binding protein called galectin-9) that binds to T-cell TIM-3 proteins to cause the infestion and apoptosis of effect T cells.
IBI104's in-body dosing induces effective internalization of TIM-3 in active T-cells to some extent, which shuts down the signal conduction of the entire TIM-3 mediated.
study also revealed that NK cells may play a key role in TIM-3 inhibitory tumor immunotherapy, while IBI104 alone can enhance in-body NK cell activity.
in preclinical mouse tumor models in the body, the effect of blocking TIM-3 alone on tumor control was limited.
when used in combination with anti-PD-1 inhibitors, IBI104 showed effective anti-tumor efficacy, and the tumors in the combined mice were significantly smaller than those in the PD-1 antibody monodynamic group.
paper notes that PD-1 inhibitors may not be sufficient to restore the ability of double-positive T-cell proliferation and killing tumor cells, while the use of TIM-3 blockers such as IBI104 has shown synergy in restoring T-cell function.
A: TIM-3 distribution in tumor micro-environment, anti-tumor effects of B:IBI104 and combined anti-PD-1 antibodies, C: tumor volume and tumor growth inhibition (TGI) ;D: animal weight during the experiment.
IBI104 showed effective anti-tumor activity in mice (Photo: Resources1) According to a Xinda Bio news release, the company is currently working on several monodrings against TIM-3 antibody IBI104, as well as new drug research projects with PD-1 monoantigen therapy.
: a novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy, Retrieved Nov 9, 2019 from the 2019 Xinda bioscics published cover paper in Antibody Therapeutics: New TIM-3 monoantimmune treatment for tumors provides a new approach. Retrieved Dec 13 2020, from Source: Medical Mission Hills